-
The National Cancer Institute has made clinical trial participation a top national priority and yet participant levels are still not perhaps where they could be. Yes, this is a big decision for any patient/physician to make as far as whether or not to enroll, but many trials are offering lifesaving...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-02-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, My Commentaries, Investors, health insurance, Pharma, Cancer, clinical trials, HMO, Pharmaceuticals, R and D, Drug Development, Cancer Institute
-
This interview from Charlie Roses touches on many items and Nobel Prize Winner Muhammad Yunus adds what he has been able to accomplish in his part of the world in Bangladesh and how some of those principles can be applied here, coming together of both sides, different minds, different ideas that can...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-28-2008
Filed under:
Filed under: Medically Related, Insurance, Other Items of Interest, My Commentaries, healthcare, Biotech, Cancer, Pharmaceuticals, R and D, Economy, Banking, Milken Institute, Mahammed Yunus, Milken, Charlie Rose
-
We all may complain and wonder about the processes of the FDA, but when you read stories like this one, it does make you wonder about the research and development in other countries and how thorough the process is, this in light of all the contaminated milk products on the market as well coming from...
-
The company has 6 months to get the shares up above $1.00 or it goes to the junk category and off the big board. Drug stores are feeling the pinch of the economic slow down, depending on where the stood financially before hand, has an effect on where they are today. Granted Rite Aid had some...
-
This article states part of the reporting system will include information on the willingness of a doctor to use genetic testing, well first of all we need to help the doctors to bring this full circle with the integration into the clinical side of this, as I have spoken to many MDs and they are aware...
-
New marketing technique going on here, gets you to the website, but no mention of the drug name . This ranks right up there with the Placebo ads from the FDA for a fake blood pressure pill , and what website will it take you to? Is there any honestly or dignity left in advertising? ...
-
This article brings up a good point, when a patient has no other choices and the potential of a new drug could offer some relief, what is the verdict at this point? The FDA has turned it's way of thinking around now to being much more conservative on the drugs that are approved. Do the drug companies...
-
It should be the discretion of individual physicians, not insurance companies or pharmacies, to substitute a branded biologic for a biosimilar, which goes back to putting the physician in the decision making process, not the non clinical analyzers. While the search for "cheap" continues...
-
Part of the success of Amgen was using a smaller amount of individuals for clinical trials, and looking at results during the trial instead of an overall evaluation process at the conclusion. It also helps keep the cost of the clinical trials down by conducting studies for biomarkers, or signature...
-
One more way for the information to run queries to cherry pick applicants is accomplished. When you apply for insurance, the fine writing will usually state that you are giving permission to check any medical information and records and, yes, this includes prescriptions. Even the $4.00 generic...
-
A new possible term in the world of Biotech, Biogenerics? We currently have Pharmacogenomics working and now perhaps an interest with the Generic Drug business investing in Biotech as well or perhaps the availability of a generic without a long patent protection period? I am not quite sure...
-
Teva also stated it plans to sue Novartis and Momenta for patent infringement. Recently in the news was the announcement to buy Bentley Pharmaceuticals. “Teva USA products are marketed to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies....
-
Thomas Pogge, Professor of Philosophy and International Affairs at Yale University in the United States to speak out on reform with the pharmaceutical industry on July 17th in the UK with a new proposal and business model proposition called the Health Impact Fund in the interest of protecting human rights...
-
The center of the investigation is whether or not the proper amount of the active ingredient was contained in the product and if the shelf life had been properly labeled according to the standards set forth by the FDA. There are efforts being made to group together on inspections with other countries...
-
With all the heat of late on financial contributions for CME credit, Pfizer is the first one out of the barrel to restructure where and where they will not offer funding. In other words it appears to be an evaluation process to make sure that the CME funds go where they should, towards education...